CreosG recruits immuno-oncology expert... "Full-scale development of cancer drugs based on vaccine platform"

CreoSG announced on the 19th that it has recruited Dr. Son Ho-seon as the head of its immuno-oncology research and development team. Marking the acquisition of an expert in the field of immuno-oncology, the company plans to accelerate the development of anticancer drugs through its proprietary universal vaccine development platform, ‘SUV-MAP,’ and expand its research into virus vector-based immunotherapies.

Dr. Son Ho-seon is a bio expert who completed his bachelor's and master's degrees at Seoul National University and earned a Ph.D. in developmental and neuroendocrinology. He conducted vaccine research at domestic bio companies based on gene analysis and recombinant technology, and worked on the development of targeted anticancer drugs with cdk4 inhibitory activity at LG Chem’s Technology Research Institute new drug development team.

Since 2011, he has served as a principal researcher at the Vaccine Research Division of the Korea Disease Control and Prevention Agency, where he was responsible for developing the smallpox vaccine. Dr. Son expanded his research to develop virus-based cancer therapeutic vaccines and demonstrated his expertise in immuno-oncology by conducting in vivo efficacy evaluation studies.

CreoSG recently initiated immuno-oncology drug development based on SUV-MAP. Since its proprietary vaccine development technology can also be applied to immuno-oncology drugs, the company is enhancing SUV-MAP to target breast cancer, colorectal cancer, and skin cancer. The company explained that it plans to develop immuno-oncology drugs with no side effects by maximizing tumor removal effects through tumor lysis based on recombinant vesicular stomatitis virus (rVSV) technology.

A CreoSG official stated, “Dr. Son will oversee CreoSG’s immuno-oncology research and lead the process of deriving anticancer drug candidates through efficacy testing,” adding, “Since Dr. Son has experience developing immuno-oncology drugs based on vaccine-related technology, synergy with SUV-MAP is expected.”

He continued, “Starting with Dr. Son, we will continuously recruit domestic experts in the anticancer drug field and establish an overseas advisory committee to strengthen our technological capabilities,” emphasizing, “We are also in discussions for collaboration with domestic and international immuno-oncology specialized companies and will accelerate anticancer drug development through joint research.”